

CURRICULUM VITAE

Robert I. Fox, M.D., Ph.D., FACP
Chief, Rheumatology Clinic
Skaggs Professor of Medicine (Emeritus)
Scripps Memorial Hospital and Research Foundation-Ximed Medical Group
La Jolla, California 92037

Consulting Rheumatologist
Kaizen Brain Center for Advanced Research
La Jolla, CA 92037

E-mail robertfoxmd@icloud.com

Date of Birth: April 13, 1946
Place of Birth: Washington, D.C.
Citizenship: United States

Address 4206 Caminito Cassis
San Diego, California, 92122

Education: Honors College, University of Michigan
BS (Biophysics) 1968 (Summa cum laude)
Medical Scientist Training program
(Combined MD-Ph. D program) 1968-74
Harvard Medical School
Cold Spring Harbor Research Labs, 1968
Massachusetts General Hospital, 1969, 1974
Albert Einstein College of Medicine, New York
Ph.D. Molecular Biology, 1972 (summa cum laude)
M.D. 1974 (summa cum laude)

Brief Chronology of Employment:

1974 - 1976	Intern and Resident in Internal Medicine, Stanford University Medical Center, Stanford, California
1976 - 1978	Fellowship in Immunology and Rheumatology, Stanford University Medical Center
1978-1979	Chief Resident in Internal Medicine, Stanford University Medical Center
1979-1980	Assistant Professor, Division of Rheumatology, Stanford University
1980 - 1987	Assistant Member in Immunology (Research), The Scripps Research Institute
1980-1999	Member, Department of Clinical Rheumatology, ScrippsHealth, La Jolla, California

1987 - present Associate Member in Immunology (Research), The Scripps Research Institute
The Scripps Research Foundation
La Jolla, CA

1999-2023. Member, Rheumatology Clinic,
Scripps Ximed Association

2023 Professor of Medicine (Emeritus)
Scripps Memorial Hospital and Research Foundation

2025 Member, Kaizen Brain Research Foundation
La Jolla, California
(Focusing on the molecular basis of fatigue and “brain fog” in patients with autoimmune disease or post-Covid)

Honors and Awards:

Undergraduate Awards at the University of Michigan (Ann Arbor, MI)
Honors College Program in Unified Science (1964-68)
Graduated Summa cum Laude (Biophysics)-1968
Phi Beta Kappa (Undergraduate Honor Society) -Vice President 1967-68
Phi Kappa Phi (Scientific Honor Society) - Vice President and President 1967-68
William I. Branstrom Award for Outstanding Academic Achievement (1968)

Patents for Drug Development, including bench to FDA approval
Mycophenolic acid (CellCept), Leflunomide, Restasis, Cevimeline

Awards during Medical and Graduate School (Combined MD-Ph.D. Program)

Graduated summa cum laude in Medicine
Alpha Omega Alpha (Medical Honor Society) – Co-President,
Ph.D. in Molecular Biology with Thesis (Molecular Biology) on Adenovirus-SV40 hybrid contamination of vaccines (1972)—summa cum laude

Smith Kline Award for postdoctoral research, Cold Spring Harbor Laboratories of Harvard Medical School, (laboratory of Prof. J.D. Watson)
Albert Einstein College of Medicine Medical Scientist Training Program (combined MD-Ph.D. Training Program in Collaboration with Harvard Medical School) with highest honors

Research Fellowship (Cambridge University, Laboratory of Molecular Biology, (laboratory of Prof. J. Crick)
Sloan-Kettering Fellowship Award for Clinical Research Excellence in Tumor Immunology,

Postgraduate Awards

Postdoctoral Fellow of the Arthritis Foundation
Member, American Board of Internal Medicine,
Fellow, American College of Physicians,

Fellow, American Society for Clinical Investigation,
Fellow, American College of Rheumatology
Master, American College of Rheumatology

President, San Diego Rheumatism Society,
Outstanding Clinical Investigator Award, American Society of Clinical
Investigation, 1997

Skaggs Award for Distinguished Clinical Research, The Scripps Research Institute,
1998

Broadhurst Distinguished Faculty Lecture Award, Harvard Medical School, 2001

Designated “Outstanding Clinical Rheumatologist, Southern California” 2002-2015

Visiting Scholar in Residence:

Chinese Academy of Rheumatology (1982, 1985, 1989, 1995, 2007, 2010)-

Peking Union Medical College and Shanghai II Medical University 1982, 1987,
2005

University of Tokyo and Keio University (1984,1987,2007)

British Rheumatology Society –St. Thomas Hospital(London), Cambridge and
Oxford University Medical School Visiting Scholar

Scandinavian Rheumatology Society (Karolinska Institute),

German Rheumatology Society (Erlangen),

Catholic University (Rome),

Italian Rheumatology Society Visiting Scholar, Florence (2007),

Indian Rheumatology Society Fellowships in Delhi and Mumbai (2008 and
2010)

Section Editor for Sjogren’s Syndrome for “UpToDate”-online medical textbook
Author and Editor “Sjogren’s Syndrome: Practical Guidelines to Diagnosis and
Therapy” (2012) Springer Publications, New York

Editor, Rheumatology Grand Rounds

Section Editor, Current Opinion in Investigational Drugs: Inflammation and
Autoimmunity

Section Editor, Current Drugs

Section Editor, Clinical Immunology

Associate Editor, Journal of Clinical Laboratory Analysis

Associate Editor, Arthritis and Rheumatism

Associate Editor, Journal of Rheumatology

Associate Editor (Rheumatology), Medscape (WebMD) (see articles on
medscape.com or WebMD.com)

Advisory Board, American College of Rheumatology for “Guidelines for
Rheumatology Referral”

Advisory Board, International Institute of Immunopathology, Cologne, Germany

Advisory Board, National Sjögren's Syndrome Foundation

Advisory Board, National Scleroderma Federation
Advisory Board, California Systemic Lupus Society
Advisory Board for Rheumatology, MedScape (internet information for physicians)
Study Section for Research Grants, American College of Rheumatology
Study Section for Postdoctoral Fellowships, Arthritis Foundation
Study Section for Multipurpose Arthritis Center, National Institutes of Health
Study Section for General Medicine, National Institutes of Health

Advisory Board FDA (CBER)—Advanced College for Rheumatology and
Inflammatory Disease
Advisory Board, American College of Rheumatology for “Standards of Care for
Sjogren’s Syndrome” and Committee for Diagnostic Criteria
Rheumatology Editor for the on-line medical textbook “UpToDate”

Principal Investigator for NIH Grant M01RR0833 (General Clinical Research Center, (GCRC) including projects:

- a) Open Label Phase II study for treatment of severe rheumatoid arthritis with azaribine plus pyridoxine (IND) (1993-present)
- b) Treatment of Patients with autoimmune disease and pathogenetic paraproteins with 2-chlorodeoxyadenosine (IND) (1993-present)
- c) Evaluation of the genetic and environmental factors in the pathogenesis of Sjogren's syndrome (1984-present)
- d) Pathogenesis of Neutropenia in Sjogren's syndrome and systemic lupus erythematosus using DNA recombinatorial phage libraries of monoclonal antibodies derived from patients (1994-present)
- e) Treatment of patients with severe rheumatoid arthritis with inhibitors of de novo pyridimide synthesis including tri-acetyl 6-azauridine

Principal Investigator for multi-center trials involving rheumatoid arthritis, Sjogren's syndrome or systemic lupus erythematosus:

- a) Double blind study of efficacy and safety of mycophenolic acid mofetil in rheumatoid arthritis (1989-1995); extension trial-present
- b) Multicenter open label trial to establish the efficacy and safety of hydroxychloroquine in patients with Sjogren's syndrome (1989-1993)
- c) Multicenter Double blind study for the use of pilocarpine in patients with Sjogren's syndrome (1993-1994) (protocol 96-05 and 06)
- d) Multicenter Trial of Tinedap in early rheumatoid arthritis (1993-1996)
- e) Multicenter Trial of Leflunomide versus Methotrexate in Rheumatoid Arthritis (1995-present) (protocol 97-06)
- f) Multicenter Trial for treatment of rheumatoid arthritis with methotrexate plus cyclosporin A (Neoral) (1996)
- g) Multicenter Trial for Cox-2 Inhibitor in treatment of rheumatoid arthritis (1996-present) (co-investigator)
- h) Multicenter Trial for Muscarinic M1 and M3 agonist (SNI-077) in treatment of Sjogren's syndrome (1997-present)
- i) Multicenter Trial for TNFRII:Fc (Enbrel) in early rheumatoid arthritis (1997-present) (protocols 16-0012 , 16-0014, and 16-0018) (protocol 97-052, 053, and 98-9032)
- j) Multicenter Trial for T-cell Receptor Vaccine in rheumatoid arthritis (Immune Response) (protocol 97-144)
- h) Prediction of response to methotrexate by detection of cytokine and metalloproteinase inhibitor levels (protocol 98-009)

PUBLICATIONS

1. Pinnell S, Fox RI, Krane S: Human collagen: its breakdown products in normal and diseased states. *Biochim Biophys Acta* **229**:119, 1971.
2. Baum S, Fox R: Components of the adenovirus 7-SV40 hybrid virus. *Proc Natl Acad Sci USA* **68**:1525, 1971.
3. Pinnell S, Fox RI, Krane S: A method for distinguishing the breakdown products of skin from bone collagen in man. *J Clin Invest* **49**:75, 1970.
4. Fox RI, Baum S: Synthesis of viral RNA during restricted adenovirus infection. *J Virol* **10**:221, 1972.
5. Fox RI: Interaction of adenovirus and simian virus 40. Univ of Michigan Microfilms, Ph.D. Thesis, 1972.
6. Davies P, Allison AC, Fox RI, Haswell D: The inhibition of phagocytosis and facilitation of exocytosis in rabbit polymorphonuclear leukocytes. *Lab Invest* **28**:16, 1973.
7. Davies P, Fox RI, Allison AC, Haswell D: Exocytosis of polymorphonuclear leukocyte lysosomal enzymes induced by cytochalasin B. *J Biochem* **128**:78, 1972.
8. Fisher M, Fox RI, Newman A: Computer diagnosis of the acutely ill patient with fever and a rash. *Int J Dermatol* **12**:59, 1973.
9. Fox RI, Baum S: Restriction of adenovirus replication in monkey cells. *Virology* **60**:45, 1974.
10. Baum S, Fox RI: Human adenovirus infection in monkey cells: An example of host restriction at a step late in replication. *Cold Spring Harbor Symp Quant Biol* **39**:567, 1974.
11. Calin A, Fox RI, Gerber R: The prognosis in Reiter's syndrome. *Ann Rheum Dis* **21**:548, 1978.
12. Fox RI, Weissman I: Moloney virus induced cell surface antigens and histocompatibility antigens are located on distinct molecules. *J Immunol* **122**:1697, 1979.
13. Humphrey D, Tsukamoto-Adey A, Witte O, Fox RI, Jerabek L, Weissman I: A comparison of Moloney lymphoma cell surface and Moloney oncornavirus antigens. *J Immunol* **123**:412, 1979.

14. Fox RI, Calin C, Gibson D, Gerber R: The chronicity of symptoms and disability in Reiter's syndrome. *Ann Intern Med* **91**:190, 1979.
15. Fox RI, Weissman I: Absence of de-repressed H-2 alloantigens on a murine lymphoma. *J Immunol* **123**:1736, 1979.
16. Levy R, Dilley J, Fox RI, Warnke R: A human thymus-leukemia antigen defined by hybridoma antibodies. *Proc Natl Acad Sci USA* **76**:6552, 1979.
17. Tsoukas CD, Fox RI, Slovin SF, Carson DA, Pellegrino M, Fong S, Pasquali J-L, Ferrone S, Kung P, Vaughan JH: T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. *J Immunol* **126**:1742-1746, 1981.
18. Fong S, Tsoukas CD, Pasquali J-L, Fox RI, Rose JE, Raiklen D, Carson DA, Vaughan JH: Fractionation of human lymphocyte subpopulations on immunoglobulin coated petri dishes. *J Immunol Methods* **44**:171-182, 1981.
19. Zipf T, Fox RI, Dilley J, Levy R: Definition of the high risk ALL patient by immunologic phenotyping with monoclonal antibodies. *Cancer Res* **41**:4786-4789, 1981.
20. Engleman E, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R: Studies on a human T lymphocyte antigen defined by monoclonal antibodies. *Proc Natl Acad Sci USA* **78**:1791-1976, 1981.
21. Fox RI, Thompson L, Huddleston J: T-gamma cells express T lymphocyte associated antigens. *J Immunol* **126**:2062-2065, 1981.
22. Fong S, Fox RI, Rose JE, Liu J, Tsoukas CD, Carson DA, Vaughan JH: Solid-phase selection of human T lymphocyte subpopulations using monoclonal antibodies. *J Immunol Methods* **46**:153-163, 1981.
23. Fox RI, Fong S, Sabharwal N, Carstens SA, Kung PC, Vaughan JH: Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. *J Immunol* **128**:351-354, 1982.
24. Fox RI, Baird S, Kung P, Levy R, Royston I: Cell surface antigens on normal and neoplastic human lymphocytes. In: **Human Cancer Markers**. Sell S, Wahren B (ed.) pp. 33-68. Humana Press, Clifton, New Jersey, 1982.
25. Tsoukas CD, Carson DA, Fong S, Slovin SF, Fox RI, Vaughan JH: Lysis of autologous Epstein-Barr virus infected B cells by cytotoxic T lymphocytes of rheumatoid arthritis patients. *Clin Immunol Immunopathol* **24**:8-14, 1982.

26. Fox RI, Carstens SA, Fong S, Robinson CA, Howell F, Vaughan JH: Use of monoclonal antibodies to analyze peripheral blood and salivary gland lymphocyte subsets in Sjogren's Syndrome. *Arthritis Rheum* **25**:419, 1982.
27. Fox RI, Harlow D, Royston I, Elder J: Structural characterization of the human T cell surface antigen (p67) isolated from normal and neoplastic lymphocytes. *J Immunol* **129**:401-405, 1982.
28. Tsoukas CD, Fox RI, Carson DA, Fong S, Vaughan JH: Molecular interactions in human T-cell-mediated cytotoxicity to Epstein-Barr virus. I. Blocking of effector cell function by monoclonal antibody OKT3. *Cell Immunol* **69**:113-121, 1982.
29. Fox RI, McMillan R, Spruce W, Tani P, Mason D: Analysis of T-lymphocytes after bone marrow transplantation using monoclonal antibodies. *Blood* **60**:578, 1982.
30. Adamson T, Fox R, Frisman D, Howell F: Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. *J Immunol* **130**:203-208, 1983.
31. Thompson LF, Saxon A, O'Connor RD, Fox RI: Ecto-5'-nucleotidase activity in human T cell subsets. Decreased numbers of ecto-5'-nucleotidase positive cells from both OKT4+ and OKT8+ cells in patients with hypogammaglobulinemia. *J Clin Invest* **71**:892-899, 1983.
32. Fox RI, Hueniken M, Fong S, Behar S, Royston I, Singhal SK, Thompson L: A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states. *J Immunol* **131**:762-767, 1983.
33. Helin H, Fox RI, Edgington T: The instructor cell for the human procoagulant monocyte response to bacterial lipopolysaccharide is a Leu 3a positive T cell by fluorescence-activated cell sorting. *J Immunol* **131**:749-752, 1983.
34. Fox RI, Adamson III TC, Fong S, Robinson CA, Morgan EL, Robb JA, Howell FV: Lymphocyte phenotype and function in pseudolymphoma associated with Sjogren's syndrome. *J Clin Invest* **72**:52-62, 1983.
35. Fox RI, Adamson III TC: Human lymphocyte cell surface antigens defined by monoclonal antibodies. In: **Clinical Laboratory Assays**, Chapt. 15. Nakamura RM, Dito WR, Tucker ES (eds.): Masson Publishing, USA, pp. 265-295, 1983.
36. Fox RI, Adamson TC, Fong S, Young C, Howell FV: Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjogren syndrome. *Diagn Immunol* **1**:233-239, 1983.

37. Vaughan JH, Carson DA, Fox RI: The Epstein-Barr virus and rheumatoid arthritis. *Clin Exp Rheumatol* **1**:265-272, 1983.
38. Spruce WE, McMillan R, Miller W, Fox R, Carson DA, Schwartz DB, Hartman GA, Renshaw LW, Beutler E: Transplantation of T-lymphocyte-depleted bone marrow between HLA-mismatched individuals. *Transplantation* **36**:369-372, 1983.
39. Young CL, Adamson III TC, Vaughan JH, Fox RI: Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. *Arthritis Rheum* **27**:32-39, 1984.
40. Thompson LF, Fox RI: Decreased T cell ecto-5'-nucleotidase activity in agammaglobulinemia patients is not due to altered proportions of helper and suppressor T cells as defined by the monoclonal antibodies OKT4 and OKT8. In: **Purine Metabolism in Man-IV, Part B**. DeBruyn CHMM, Simmonds HA, Muller MM (eds.) pp. 153-158. Plenum Publishing Corp., New York, 1984.
41. Fox RI, Young CL, Adamson III TC, Frisman DM: Characterization of lymphocytes in tissue lesions from patients with rheumatoid arthritis and Sjogren's Syndrome using monoclonal antibody SC1. In: **Human Leukocyte Markers Detected by Monoclonal Antibodies**. Boumsell L, Bernard A (eds.) pp. 552-557. Springer-Verlag, Berlin 1984.
42. Dillman RD, Shawler DL, Frisman DM, Fox RI, Royston I: Characterization of a monoclonal antibody that reacts with activated/proliferating cells, and subsets of leukemia cells. *J Biol Response Mod* **3**:26-38, 1984.
43. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE: Beneficial effect of artificial tears made with autologous serum in patients with Keratoconjunctivitis Sicca. *Arthritis Rheum* **27**:459-461, 1984.
44. Fox RI, Fong S, Tsoukas CD, Vaughan JH: Characterization of recirculating lymphocytes in rheumatoid arthritis patients: Selective deficiency of natural killer cells in thoracic duct lymph. *J Immunol* **132**:2883-2887, 1984.
45. Federici AB, Fox RI, Espinosa LR, Zimmerman TS: Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment. *Arthritis Rheum* **27**:1046-1049, 1984.
46. Epstein AL, Marder RJ, Winter JN, Fox RI: Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. *J Immunol* **133**:1028-1036, 1984.

47. Fox RI, Howell FV, Bone RC, Michelson PE: Primary Sjogren's syndrome: Clinical and immunopathologic features. *Semin Arthritis Rheum* **14**:77-105, 1984.
48. Vaughan JH, Fox RI, Abresch RJ, Tsoukas CD, Curd JG, Carson DA: Thoracic duct drainage in rheumatoid arthritis. *Clin Exp Immunol* **58**:645-653, 1984.
49. Sportsman JR, Park MM, Cheresch DA, Fukuda MM, Elder JH, Fox RI: Characterization of a membrane surface glycoprotein associated with T-cell activation. *J Immunol* **135**:158-164, 1985.
50. Fox RI, Hugli TE, Lanier LL, Morgan EL, Howell F: Salivary gland lymphocytes in primary Sjogren's syndrome lack lymphocyte subsets defined by Leu 7 and Leu 11 antigens. *J Immunol* **135**:207-214, 1985.
51. Carson DA, Fox RI: Structure and function of synoviocytes. In: **Arthritis and Allied Conditions**. McCarty DJ (eds.): pp. 257-269. Lea and Febiger, Philadelphia, 1985.
52. Fong S, Chen PP, Gilbertson TA, Fox RI, Vaughan JH, Carson DA: Structural similarities in the kappa light chains of human rheumatoid factor paraproteins and serum immunoglobulins bearing a cross-reactive idiotype. *J Immunol* **135**:1955-1960, 1985.
53. Fox RI, Michelson PE, Howell FV: Ocular and oral problems in arthritis. How to recognize, when to refer. *Postgrad Med* **78**:87-97, 1985.
54. Isakov N, Fox RI, Dixon F, Theofilopoulos A, Altman A: Staining and fluorescence-activated cell sorter analysis of human lymphocytes using antibodies to a short, chemically synthesized human IL-2 peptide. *Cell Immunol* **94**:491-499, 1985.
55. Bone RC, Fox RI, Howell FV, Fantozzi R: Sjogren's Syndrome: New immunologic assessments for a persistent clinical problem. *Laryngoscope* **95**:295-299, 1985.
56. Fantozzi R, Bone R, Fox RI: Extraglandular Warthin's tumors. *Laryngoscope* **95**:682-688, 1985.
57. Fox RI, Theofilopoulos AN, Altman A: Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjogren's syndrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL 2. *J Immunol* **135**:3109-3115, 1985.

58. Fox RI, Lotz M, Rhodes GH, Vaughan JH: Epstein-Barr virus in rheumatoid arthritis. In: **Immunologic Aspects of Rheumatic Disease**, Vol. 11. Williams R, Dickens D. (eds.) pp. 665-688. W.B. Saunders, England 1985.
59. Esparza I, Fox RI, Schreiber RD: Interferon-gamma dependent modulation of C3b receptors (CRI) on human peripheral blood monocytes. *J Immunol* **136**:1360-1365, 1986.
60. Fox RI, Chen PP, Carson DA, Fong S: Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjogren's syndrome. *J Immunol* **136**:477-483, 1986.
61. Fox RI, Sportsman R, Rhodes GH, Luka J, Pearson G, Vaughan JH: Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus encoded EBNA-1 antigen. *J Clin Invest* **77**:1539-1547, 1986.
62. Fox RI, Robinson C, Curd J, Kozin F, Howell FV: Sjogren's syndrome: Proposed criteria for classification. *Arthritis Rheum* **29**:577-585, 1986.
63. Fong S, Chen PP, Gilbertson TA, Weber JR, Fox RI, Carson DA: Expression of three cross-reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults. *J Immunol* **137**:122-128, 1986.
64. Fox RI, Chilton T, Rhodes G, Vaughan JH: Lack of reactivity of rheumatoid arthritis synovial membrane with cloned EBV DNA probes. *J Immunol* **137**:498-501, 1986.
65. Jalkanen S, Steere AC, Fox RI, Butcher EC: A distinct endothelial cell recognition system controlling lymphocyte traffic into inflamed synovium. *Science* **233**:556-558, 1986.
66. Fox RI, Bumol T, Fantozzi R, Bone R, Schreiber R: Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sjogren's syndrome. *Arthritis Rheum* **29**:1105-1111, 1986.
67. Fox RI, Pearson G, Vaughan JH: Detection of Epstein-Barr virus associated antigens and DNA in salivary gland biopsies from patients with Sjogren's syndrome. *J Immunol* **137**:3162-3168, 1986.
68. Fox RI, Carson DA, Chen P, Fong S: Characterization of a cross reactive idiotype in Sjogren's syndrome. *Scand J Rheumatol* **61**:83-88, 1986.
69. Fox RI, Howell FV: Oral problems in patients with Sjogren's syndrome. *Scand J Rheumatol* **61**:194-200, 1986.

70. Fox RI, Robinson C, Curd J, Michelson P, Bone R, Howell FV: First international symposium on Sjogren's syndrome: Suggested criteria for classification. *Scand J Rheumatol* **62**:28-30, 1986.
71. Fong S, Chen PP, Fox RI, Goldfien RD, Silverman GJ, Radoux V, Jirik F, Vaughan JH, Carson DA: Rheumatoid factors in human autoimmune disease: Their origin, development and function. *Path Immunopath Res* **5**:305-316, 1986.
72. Fox RI, Carson DA: Monoclonal antibodies and construction of antibody to specific determinants. In: **Rheumatology & Immunology**, 2nd Edition, Bennett JC, Cohen AS (eds.) pp. 438-443, Grune & Stratton, New York, 1986.
73. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S: Rheumatoid factors and immune networks. *Ann Rev Immunol* **5**:109-126, 1987.
74. Freimark B, Lanier L, Phillips J, Quertermous T, Fox RI: Comparison of Tcell receptor gene rearrangements in patients with large granular Tcell leukemia and Felty's syndrome. *J Immunol* **138**:1724-1729, 1987.
75. Fox RI: Immunoregulation in Sjogren's syndrome. *Eur J Immunol Immunopharmacol* **7**:60-68, 1987.
76. Fox RI, Scott S, Houghton R, Whalley A, Geltofsky J, Vaughan JH, Smith R: A synthetic peptide derived from the Epstein-Barr virus encoded early diffuse antigen (EA-D) reactive with human antibodies. *J Clin Lab Anal* **1**:140-145, 1987.
77. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik F, Goldfien RD, Fox RI, Silverman GJ, Fong S: Molecular basis for the cross-reactive idiotypes on human anti-IgG autoantibodies (rheumatoid factors) In: **Autoimmunity and Autoimmune Disease**. Ciba Foundation Symposium 129, John Wiley & Sons, New York, pp. 123-134, 1987.
78. Fox RI, Chilton T, Scott S, Benton L, Howell FV, Vaughan JH: Potential role of Epstein-Barr virus in Sjogren's syndrome. *Rheumatic Disease Clinics of North America* **13**:275-292, 1987.
79. Fong S, Chen P, Carson DA, Fox RI: 1. Rheumatoid factor in Sjogren's syndrome. In: **Sjogren's Syndrome: Clinical and Immunological Aspects**. Talal N, Moutsopoulos HM, Kassan SS (Eds.) Springer-Verlag, New York, pp. 203-217, 1987.

80. Freimark B, Fox RI: Immunoglobulin-gene rearrangement in benign lymphoepithelial lesions. *N Eng J Med* **317**:1158, 1987.
81. Carson DA, Chen PP, Kipps TJ, Radoux V, Jirik FR, Goldfien RD, Fox RI, Silverman GJ, Fong S: Idiotypic and genetic studies of human rheumatoid factors. *Arthritis Rheum* **30**:1321-1325, 1987.
82. Fox RI, Howell FV: Reactivation of Epstein-Barr virus in Sjogren's syndrome. *La Ricerca Clin Lab* **17**:273-277, 1987.
83. Fox RI, Robinson C, Curd J, Howell F: Current comment on "Diagnosis of Sjogren's syndrome". *Arthritis Rheum* **30**:955-956, 1987.
84. Josephs SF, Buchbinder A, Streicher HZ, Ablashi DV, Salahuddin SZ, Guo H-G, Wong-Staal F, Cossman J, Raffeld M, Sundeen J, Levine P, Biggar R, Krueger GRF, Fox RI, Gallo RC: Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B-cell lymphoma tissues of three patients. *Leukemia* **2**:132-135, 1988.
85. Fong S, Chen PP, Fox RI, Goldfien RD, Radoux V, Silverman GJ, Crowley JJ, Roudier J, Carson DA: The diversity and idiotypic pattern of human rheumatoid factors in disease. In: **Concepts in Immunopathology** **5**:168-191. Cruse JM, Lewis Jr RE (Eds.) , S. Karger, Basel, , 1988.
86. Fox RI, Fong S, Chen PP, Kipps TJ: Autoantibody production in Sjogren's syndrome: A hypothesis regarding defects in somatic diversification of germ line encoded genes. *In Vivo* **2**:47-56, 1988.
87. Fox RI: Epstein-Barr virus and human autoimmune diseases: possibilities and pitfalls. *J Virol Methods* **241**:1218-1221, 1988.
88. Fox RI, Lotz M, Carson DA: Structure and function of synoviocytes. In: **Arthritis and Allied Conditions**, 11th Ed., D.J. McCarty (Ed.), Lea & Febiger, Philadelphia, pg. 273-288, 1988
89. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV: Treatment of primary Sjogren's syndrome with hydroxychloroquine. *Amer J Med* **85**:62-67, 1988.
90. Piller F, Piller V, Fox RI, Fukuda M: Human T-lymphocyte activation is associated with dramatic changes in O-glycan biosynthesis. *J Bio Chem* **263**:15146-15150, 1988.
91. Saito I, Fox RI, Walker LE, Fernsten PD, Howell FV: Monoclonal antibodies potentially useful for diagnosis of squamous cell oral carcinoma. *J Clin Lab Analysis* **2**:235-240, 1988.

92. Fox RI, Carson DA, Fei HM, Saito I: The potential role of infectious agents in chronic autoimmune diseases. In: **Recent Advances in Autoimmunity and Tumor Immunology**. F. Dammacco (Ed.), Edi-Ermes, Milan, pg. 3-14, 1988.
93. Fox RI, Saito I: Clinical syndromes associated with Epstein-Barr virus. In: **Epstein-Barr Virus and Human Disease II**, Levine PH, Ablashi DV, Nonoyama M, Pearson GR, Glaser R (Eds.), Humana Press, Clifton, NJ, pg 212-222, 1988
94. Freimark B, Pickering L, Concannon, P., Fox R: Nucleotide sequence of a uniquely expressed human T cell receptor b chain variable region gene (Vb) in Sjogren's syndrome. *Nucleic Acids Res* **17**:455, 1989.
95. Kipps TJ, Tomhave E, Chen PP, Fox RI: Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren's syndrome. *J Immunol* **142**:4261-4268, 1989.
96. Saito I, Servenius B, Comptom T, Fox RI: Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. *J Exp Med* **169**:2191-2198, 1989.
97. Fox RI, Robinson CA, Williams GW, Curd JG, Colwell CW, Bumol TF: Future approaches to the diagnosis and therapy of rheumatoid arthritis. In: **Immunomodulators in the Rheumatic Diseases**. Weinblatt M, Furst DE (Eds.) Marcel Dekker, Inc. 223-256, 1989
98. Fox RI, Saito I, Chan EK, Josephs S, Salahuddin SZ, Ahlashi DV, Hu P-P, Chen S-L: Viral genomes in lymphomas of patients with Sjogren's syndrome. *J Autoimmunity*, **2**:449-455, 1989.
99. Mosier DE, Gulizia RJ, Baird SM, Spector S, Spector D, Kipps TJ, Fox RI, Carson DA, Cooper N, Richman DD, Wilson DB: Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. In: **Proceedings of EMBO Symposium**, 1989.
100. Freimark B, Fantozzi R, Bone R, Bordin G, Fox R: Detection of clonally expanded salivary gland lymphocytes in Sjogren's syndrome. *Arthritis Rheum*, **32**:859-869, 1989.
101. Chan EKL, Sullivan KF, Fox RI and Tan EM: Sjogren's syndrome nuclear antigen B (La): cDNA cloning, structural domains, and autoepitopes. *J Autoimmunity*, **2**:321-327, 1989.

102. Fox R, Dotan I, Compton T, Fei H, Hamer M, Saito I: Use of DNA amplification methods for clinical diagnosis in autoimmune disease. *J Clin Lab Analysis*, **3**:378-387, 1989.
103. Saito I, Servenius B, Compton T, Fox RI: Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjögren's syndrome. *J. Exp. Med.* **169**:2191-2198, 1989.
104. Mosier DE, Gulizia RJ, Wilson DB, Baird SM, Spector SA, Spector DH, Richman DD, Fox RI and Kipps TJ: Elements of the human immune system: Studies of mature lymphoid cells following xenotransplantation of SCID mice. In: **Current Topics in Microbiology and Immunology** (ed. M.J. Bosma), **152**:150-155, 1989.
105. Cannon MJ, Pisa P, Fox RI, Cooper NR: Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. *J Clin Invest.* **85**:1333-1337, 1990.
106. Ben-Chetrit E, Fox RI, and Tan EM: Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. *Arthritis & Rheum.* **33**:349-355, 1990.
107. Cannon MJ, Pisa P, Fox RI, Cooper NR: Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. *J. Clin. Invest.* **85**:1333-1337, 1990.
108. Fox RI, Howell FV, Friedlaender M: Causes. IN: **The Sjögren's Syndrome Handbook**. Ed. S. Carsons, J.J. Sciubba, N. Talal (Sjögren's Syndrome Foundation, Inc. Port Washington, NY). pgs. 13-18 1990.
109. Fox RI, Pisa E, Pisa P, Compton T: DNA amplification methods for clinical diagnosis in autoimmune diseases. IN: **Autoimmunity and Molecular Biology**. ed. Ernest Brahn (Little and Brown, Co., Boston, MA). 1990.
110. Fox RI, Saito I, Compton T: Strategies to search for infectious agents in autoimmune disease. N: **Autoimmunity and Molecular Biology**. ed. Ernest Brahn (Little and Brown, Co., Boston, MA)., pgs 225-230, 1990.
111. Fox RI, Robinson CA, Williams GW, Curd JG, Colwell CW: Future approaches to the diagnosis and therapy of rheumatoid arthritis IN: **Immodulators in the Rheumatic Diseases, Chapter 8**. ed. Furst/Weinblatt (Marcel Dekker, inc., New York), Chapter **8**:223-256, 1990.
112. Fujikura S, Davis PA, Prindiville T, Leung P, Fox RI, Gershwin ME: Autoantibodies to purified mitochondrial 2 OXO acid dehydrogenases in patients with Sjögren's syndrome. *J. Rheum.* **171**:453-457, 1990.

113. Saitoh O, Piller F, Fox RI, and Fukuda M: T-lymphocytic leukemia cells express complex O-linked oligosaccharides on a major sialoglycoprotein, leukosialin. *Blood*, **77**:1491-1499, 1991.
114. Fox RI, Kang H-I: Structure and Function of Synoviocytes. In **Arthritis and Allied Conditions-A Textbook of Rheumatology** (D.J. McCarty and B. Koopman, eds) Lea & Febiger, Malvern Pa. 1991.
115. Fox RI: Sjögren's Syndrome. pgs 175-181 in: **Current Therapy in Allergy, Immunology, and Rheumatology** (L. Lichtenstein and A.S. Fauci, eds) B.C. Decker, Inc. Philadelphia, PA. 1991.
116. Fox, RI, Luppi, M, Kang, HI, Pisa, P: Reactivation of Epstein-Barr virus in Sjögren's syndrome: IN: **Springer Seminars in Immunopathology** (J.W. Sixbey, T. Ooka, eds.). Springer-Verlag GmbH & Co. KG, Heidelberg, Germany. **13**:217-231, 1991
117. Fei HM, Scharf S, Erlich H, Peebles C, Tan E, Fox RI: The relationship between HLA-D region gene and primary Sjögren's syndrome. *Natl. Med. J. China*. **71**:555-559, 1991.
118. Fei HM, Scharf S, Erlich H, Peebles C, and Fox R: Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody SS-B production. *J Clin Lab Analysis*. **5**:382-391, 1991.
119. Pisa EK, Pisa P, Fox RI: High frequency of t(14;18) translocation in salivary gland lymphomas from Sjögren's syndrome patients. *J. Exp. Med*. **174**:1245-1250, 1991.
120. Lappi DA, Martineau D, Mahe, PA, Florkiewicz RZ, Buscaglai M, Gonzalez AM, Farris J, Fox RI, Baird A: Basic fibroblast growth factor in cells derived from Dupuytren's contracture: Synthesis, presence and implications for the therapy of the disease. *J. Hand Surg.*,1991, **In press**.
121. Pisa P, Cannon MJ, Pisa EK, Cooper NR, Fox RI: Epstein-Barr virus induced lymphoproliferative tumors in SCID mice are oligoclonal. *Blood*, **79**: 173-179, 1992.
122. Fox RI: Summary of the Third Internations Sjögren's Syndrome Symposium. (Special Article) *Arthritis & Rheum*. **34**:1-2, 1992
123. Fox RI, Luppi M, Pisa P, Kang HI: Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis. *J. Rheum*. **19**:18-24, 1992.

124. Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GRV. Fox RI: Antiphospholipid antibodies and HLA associations in primary Sjögren's syndrome. *Annals Rheum Diseases*. **51**:495-498, 1992
125. Gonzalez AM, Buscaglia M, Fox RI, Isacchi, A, Sarmientos, P, Fassis, J, Ong, M, Martineau, D, Lappi DA, Baird A: Basic fibroblast growth factor in Dupuytren's Contracture: Implications for the pathogenesis of the disease. *Am. J. Pathology*. **141**:661-671, 1992.
126. Moorhouse DF, Fox RI, Powell HC: Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy. *Acta Neuropathol*. **84**:484-494, 1992.
127. Fox RI, Chan EK, and Kang HI: Laboratory evaluation of patients with Sjögren's syndrome. *Clinical Biochem*. **25**:213-222, 1992.
128. Fox RI: Treatment of patients with Sjögren's syndrome. In: **Rheumatic Disease Clinics of North America**. Fox RI (ed) (W.B. Saunders Co.) Philadelphia, PA. **18**:699-709, 1992
129. Fox RI, Kang HI: Pathogenesis of Sjögren's syndrome. In: **Rheumatic Disease Clinics of North America**. Fox RI (ed) (W.B. Saunders Co.) Philadelphia PA. **18**:517-538, 1992
130. Fox RI, Kang H-I: Genetic and environmental factors in systemic sclerosis. *Current Opinion in Rheum*. **4**:857-861, 1992.
131. Fong S, Chen P, Carson DA, Fox RI. Rheumatoid factor in Sjögren's syndrome. In: **Sjögren's syndrome: Clinical and Immunologic Aspects**. (eds. Talal N, Moutsopoulos HM and Kassan SS) (Springer-Verlag) New York. 203-217, 1992.
132. Fox RI, Wilson C: Sjögren's syndrome: The association of interstitial nephritis and keratoconjunctivitis sicca. IN: **A Textbook of Diseases Affecting the Eye and Kidney**. L. Regenbogen, H. Eliahou, Ed. (Karger-Basel Company,) In press, 1992.
133. Fox RI and Kang H: Mechanism of Action of Hydroxychloroquine as an Anti-Rheumatic Drug. *Lupus*: **2**:9-12, 1993.
134. Fox RI, Kang H-I: Structure and function of synoviocytes. In: **Arthritis and Allied Conditions, 11th Edition**. McCarthy, DJ, Koopman, WJ (eds) (Lea & Febiger) Philadelphia & London, **1**:263-278, 1993.

135. Fox RI, Pisa P, Pisa EK, Kang, H-I. : Lymphoproliferative disease in SCID mice reconstituted with human Sjögren's syndrome lymphocytes. *J. Clinical Lab Analysis.* **7**:46-56, 1993.
136. Fox, RI, Kang, H-I.: Sjögren's Syndrome: Pathogenesis and Treatment. In **Textbook of Rheumatology 4th Edition** (Kelley, WN, Harris, Jr., ED, Ruddy, S., Sledge, CB. eds.). W.B. Saunders Company, Philadelphia, PA. **2**:931-942, 1993.
137. Fox,RI and Wilson, C. Sjogrens Syndrome: The Association of Keratoconjunctivitis and Interstitial Nephritis. *In Diseases of the Eye and Kidney* (ed. Reginbottom, L.) Karger. 266-277, 1993.
138. Kang HI, Fei HM, Saito I, Shun-le C, Dong Y, Chan E, Bugawan TL, Erlich HA, Fox RI: Comparison of HLA-class II genes in Caucasoid, Chinese, Japanese patients with primary Sjögren's syndrome. *J. Immunol.* **150**: 3615-3623, 1993.
139. Fox RI and Kang H: Hydroxychloroquine: Mechanism of Action, *Seminars in Rheum.* **23**:82-91, 1993.
140. Fox RI, Luppi M, Kang, HI, Ablashi D, Josephs S: Detection of human herpes virus-6 DNA in a lymphoma arising in a patient with Sjögren's syndrome. *J. Rheum.* (in press), 1993.
141. Fox RI. Sjögren's Syndrome. In: **Textbook of Medicine.** Stein, E, Zvaifler, N. (eds) (in press). 1993
142. Fox, RI, Kang, H-I.: Sjögren's Syndrome: An Autoimmune Exocrinopathy. In **The Molecular Pathology of Autoimmunity** (C. Bona, K. Simonovitch, A.N. Theofilopoulos, M. Zanetti, eds.). Harwood Academic Company, Switzerland. 317-333, 1993.
143. Fox, RI and Saito, I., Sjogren's syndrome:Immunologic and Neuroendocrine Mechanisms, in **The Lacrimal Gland, Tear Film, and Dry Eye Syndromes: Basic Science and Clinical Relevance** (ed. D. Sullivan), Plenum Publishing, Philadelphia, PA (1994) Plenum (London), pgs. 609-621
144. Alpert, S.,Kang, H., Weissman,I. and Fox, R., Granzyme Expression in Sjogren's Syndrome. *Arth Rheum* **37**: 1048-1055, 1994
145. Kang HI,, Ando D, Abrams J , Fox RI: Cytokine transcription in salivary gland biopsies of Sjögren's syndrome. *J. Immunol.* **151**: 132-142, 1994
146. Fox, RI : Sjogren's Syndrome in "**Treatment of Rheumatic Disease**" (ed. Weinblatt, M. and Weissman, M.) Saunders, Philadelphia pgs. 68-78, 1994

147. Fox RI, Saito I: Summary of the IVth International Sjogren's Syndrome Meeting. *Arthritis Rheum* 37:771-2, 1994
148. Fox RI, Koh K, Saito, I. "Viral Factors in Sjogren's Syndrome." IN: *Sjogren's syndrome: State of the Art* (Homma M., Sugai S, . Tojo, T., Miyasaka, N., Akizuki, M., eds) Kugler, NY, NY 163-173, 1994
149. Fox RI, Koh K, Pisa, P. and Saito, I. "Lymphoproliferation in Sjogren's Syndrome." IN: *Sjogren's syndrome: State of the Art* (Homma M., Sugai S, . Tojo, T., Miyasaka, N., Akizuki, M., eds) Kugler, NY, NY 193-199, 1994
150. Fox RI: Epidemiology, pathogenesis, animal models, and treatment of Sjogren's syndrome. *Curr Opin Rheumatol* 6:501-8, 1994
151. Fox, RI : Systemic Diseases Associated with the Dry Eye in *Int. Clinics Opth.* 34: 71-87. 1994
152. Zeballos RS, Fox RI, Cheresch DA, McPherson RA: Anti-glycosphingolipid autoantibodies in rheumatologic disorders. *J Clin Lab Anal* 8:378-84, 1994
161. Fox R: Systemic Diseases Associated with the Dry Eye. *Int. Clin Opthal* 34: 71-84, 1994
153. Fox, R. and Saito, I. "Diagnostic Issues: Criteria for the Diagnosis of Sjogren's Syndrome," *Rheum Dis Clin NA* 20: 391-408, 1994
154. Fox, R. "Sjogren's Syndrome: An autoimmune exocrinopathy " in *The Molecular Pathology of Autoimmune Diseases* (ed. Bona, Siminovitch, Zanetti, Theofilopoulos) Harwood (1995) Switzerland pg 317-345
155. Fox RI, "Antimalarial Drugs" In: **Arthritis and Allied Conditions, 12th Edition.** McCarthy, DJ, Koopman, WJ (eds) (Lea & Febiger) Philadelphia & London, **pg 615-625, 1995**
156. Fox, RI: Sjogren's Syndrome in "**Clinical Immunology**" (ed. R. Rich, B. Schwartz, W. Shearer, and W. Strober), Mosby Year Book, St. Louis (1995), pgs. 1145-1155
157. Fox R: Sjogren's Syndrome: Clinical Aspects and Therapy: Summary for Vth International Symposium on Sjogren's Syndrome. *Clinical Rheumatology* 14: 17-19, 1995

158. Fox R: Antimalarial Drugs: Mechanism of Action in Autoimmune Disease and Prospects for Drug Development. Clinical Immunotherapeutics 4:1-15, 1995
159. Fox, R. "Sjogren's syndrome: Immunologic and Neuroendocrine Mechanisms" Adv Exp Med and Biol 350: 609-623 (1995)
160. Fox R: "Antimalarial Medications" Arthritis and Allied Conditions, 13th edition (ed. W. Koopman) Williams and Wilkins, Baltimore, 671-678, 1996
161. Fox, R: Sjogren's Syndrome. Current Opinion in Rheumatology 7: 409-414, 1995
162. Fox, R. and Saito, I: Sjogren's Syndrome, Clinical Immunology, 1145-1153, 1995 (ed. Rich, Fleisher, Schwartz, Shearer, Strober) Mosby, St. Louis, MO
163. Fox, R. (1996) "Sjogren's syndrome: Diagnosis and Treatment" in **Textbook of Rheumatology** (ed Kelly, Harris, Ruddy, Sledge) Saunders, Philadelphia, pgs. 931-934
164. Fox R: Sjogren's syndrome: Immunobiology of exocrine gland dysfunction., Adv Dental Res 10:1-6, 1996
165. Fox, R. (1997) " Sjogren's Syndrome" in Current Diagnosis 9), (ed. Conn, R. , Borer, W. and Snyder, J) Saunders, Philadelphia 1053-1059.
166. Fox R (1996): Classification and Mechanism of Action for Therapeutic Agents used in Autoimmune Disease. Principles of Immunosuppressive Drug Development (editor, R. Lieberman, A. Mukherjee), Landes, Philadelphia pg 117-129
167. Fox R and Theofilopoulos, A (1996): "Pathogenesis of Autoimmune Disease" Principles of Immunosuppressive Drug Development (editor R. Lieberman), (editor, R. Lieberman, A. Mukherjee), Landes, Philadelphia pg 81-93
168. Fox R: (1996) "Special Article: Vth International Symposium on Sjogren's Syndrome." Arthritis and Rheumatism 39: 195-196
169. Fox, R: (1996) "Antimalarial Drugs: Mechanism of Action." Lupus 5: 1-14

170. Fox, R. Treatment of Primary Sjogren's syndrome with antimalarial drugs. Lupus (1996)5: 31-37
171. Fox, R. and Theophilopoulos, A. (1996), "Sjogren's Syndrome: Evolving Concepts of Pathogenesis and Therapy," Expert Opinion Invest Drugs 5: 1-27
172. Fox, R. (1997) Sjogren's Syndrome, Textbook of Medicine 5th Edition (ed. Stein, Zvaifler) Mosby, St. Louis, MO. Chapter 58, pgs 5005-5017
173. Fox, R. and Morris, R. (1997) "Inhibitors of De Novo Nucleotide Synthesis for treatment of rheumatoid arthritis" in Novel Therapeutic Agents for the Treatment of Autoimmune Diseases (ed. Strand, V., Scott, D. and Simon, L.), Marcel Dekker, New York 257-286)
174. Fox, R. (1996) Sjogren's Syndrome: Genetics, Pathogenesis, and Therapy, Current Opinion in Rheumatology 8: 438-445
175. Fox, R. (1977) Sjogren's Syndrome (Current Diagnosis) in Current Diagnosis 9 (ed. Conn, R., Borer, W. and Snyder, W.) Saunders, Philadelphia 1053-1059
176. Fox, R. (1998) "Sjogren's Syndrome" in Primer of Rheumatic Disease The Arthritis Foundation, Atlanta, GA 2683-386
178. Fox, R. (1997) Sjogren's syndrome: Pathogenesis and new approaches to therapy (ed. D. Sullivan) Proc Soc. Exp Biol Med (in press)
179. Stern, M. and Fox, R. (1997) The ocular surface, lacrimal lands, and neural innervation form a functional unit: implications for autoimmune disease pathogenesis and treatment, Proc Soc Exp Biol Med 252: 138-153
180. Fox, R. (1997) Sjogren's Syndrome: Current issues in diagnosis and pathogenesis. Clinics in Laboratory Medicine: 17: 431-444 "Progress and Controversies in Autoimmune Disease Testing: Sjogren's syndrome"
181. Fox R: Sjogren's syndrome: Causes. **Sjogren's syndrome Handbook** (ed. E. Harris) Oxford University Press 1998: 23-38
182. Pancook, J., Reisfeld, R., Varki, N., Vitiello, A., Fox, R. and Montgomery, A. (1997). Expression and regulation of neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J. Immun.158: 4413-4421
183. Fox, R. (1999) Clinical and Laboratory Evaluation of rheumatoid arthritis. American Society of Clinical Pathology (ed. R. Nakamura, D. Bylund, and D. Keren) (in press)

184. Fox, R. and Maruyama, T. (1997). Sjogren's Syndrome: Clinical Spectrum and Pathogenesis. *Current Opinion in rheumatology* 9:393-399
184. Fox, R., Casiano, C., and Stern, M. (1999). Sjogren's syndrome: Review of current issues of pathogenesis, *Arth Rheum*, in press
185. Fox, R. (1998) Leflunomide: Proposed Mechanism of Action in Rheumatoid Arthritis, *J. Rheum.* 25:20-26
186. Stern, M., Beuerman, R. Fox, R., Gao, J., Mircheff, A., and Pflugfelder, S., (1997) The ocular surface in dry eye: a therapeutic target. *Proc Soc Opth. Europe* (editor I. Suveges, P. Follmann) Monduzzi, Bologna (Italy) pg 911-919
187. Fox, R., Stern, M. and Cassiano, C. (1998). Sjogren's syndrome: Update on Pathogenesis. *Rheumatology Highlights* (editor: P. Emmerly) Health Press, Oxford 1: 22-27
188. Fox, R. (1998). Tumor Necrosis Factor: A target for drug therapy in autoimmune diseases. *Current Drugs* (Oxford, UK) 88: 98-99
89. Fox, R., Maruyama, T., Tornwald, J. (1998) Sjogren's Syndrome: Current issues in diagnosis and pathogenesis. *Current Opinion in Rheumatology* 10:446-456
190. Fox, R.I., *Sjogren's syndrome. Pathogenesis and new approaches to therapy.* *Adv Exp Med Biol*, 1998. **438**: p. 891-902.
191. Stern, M.E., *et al.*, *A unified theory of the role of the ocular surface in dry eye.* *Adv Exp Med Biol*, 1998. **438**: p. 643-51
192. Fox, R., *Sjogren's Syndrome*, in *Primer on the Rheumatic Diseases*, J. Klippel, Editor. 1998, Arthritis Foundation: Atlanta, Georgia. p. 283-286.
193. Friedlaender, M.H. and R.I. Fox, *Punctal occlusion for the treatment of dry eye.* *Adv Exp Med Biol*, 1998. **438**: p. 1017-20.
194. Storgard, C., Stupack, D., Cherish, D., Fox, R (1999). Regression of angiogenesis and of arthritis with cyclic peptide inhibitors to integrin $\alpha v \beta 3$. *J Clin Invest*-103: 47-54
195. Weinblatt, M., Kremer, J., Fox, R.. et al (1999) Treatment of Active Rheumatoid Arthritis with Methotrexate plus a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein(etenercept): a phase III randomized, double-blind, placebo-controlled trial *New Engl J. Med* 340:253-259

196. Fox, R. and Stern, M. (1998) Sjogren's syndrome: clinical spectrum and pathogenesis, pg 13-23 in Rheum Highlights (Editor Paul Emery), Heath Press Oxford, UK
197. Fox, R., Herrmann, M., Kirschbaum, B., Wahl, G. and Morris, R. (1999) Mechanism of action of leflunomide in rheumatoid. *Clinical Immunology* 93: 198-208
198. Dore, R., Clements, P., Fox, R., Furst, D. Kaplan, H. and Kitridou, R. (1999) American College of Rheumatology Guidelines for rheumatology referral. Primary and Pharmaceutical Care (American College of Rheumatology publications, Atlanta, Georgia)
198. Giordanengo, V., Fuzibet, G., Fox, R. Fukuda, M. and Lefebvre, JC (1998) Inverse proportions of activated and CD4 circulating lymphocytes in AIDS patients *Lancet* (in press).
199. Strand, V, R Fox, S Cohen, M Schiff, A Weaver, R Fleischmann, G Cannon, L Moreland, N Olsen, D Furst, J Caldwell, J Kaine, J Sharp, F Hurley and I Loew-Friedrich. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Leflunomide Rheumatoid Arthritis Investigators Group [In Process Citation]. Arch Intern Med* 1999; 159: 2542-50.
200. Fox, R. and Schur, P. (1999) Leflunomide for the treatment of rheumatoid arthritis. *Textbook of Medicine: Up to Date-On the Net*, (edited P. Schur), Harvard University Press (in press as On Line Journal)
201. Fox, R. 1999. Leflunomide as an immunomodulatory drug for autoimmune diseases. *Cur Practice in Medicine* (47: 38-45)
202. Fox, R, J Tornwall and P Michelson. Current issues in the diagnosis and treatment of Sjogren's syndrome. *Curr Opin Rheumatol* 1999; 11: 364-71.203.
203. Fox, R., Tornwall, J., and Michelson, P. (2000) Sjogren's Syndrome: Approaches to treatment. in *Treatment of Rheumatic Diseases*, (ed. Weisman, M.) Saunders, Philadelphia (pgs 1027-1037)
204. Fox, R., Herrmann, M., Kirschbaum, R., Wahl, G. and Morris, R.,(1999) How Does Leflunomide Modulate the Immune Response in Rheumatoid Arthritis. *BioDrugs* 12:301-315
205. Kremer, J. and Fox, R. (1999) Leflunomide, a novel disease modifying agent for rheumatoid arthritis. In **Arthritis and Allied Conditions-A Textbook of**

Rheumatology (D.J. McCarty and B. Koopman, eds) Lea & Febizger, Malvern PA (in press)

206. Fox, R. (2000) Hydroxychloroquine and Antimalarial Medications
In **Arthritis and Allied Conditions-A Textbook of Rheumatology** (D.J. McCarty and B. Koopman, eds) Lea & Febiger, Malvern Pa. (in press)
207. Fox, R. (2000) Sjogren's Syndrome: systemic manifestations of keratoconjunctivitis sicca. in Clinics in Dermatology (ed. P. Sugarman) (in press)
208. Fox, R. (2000) Inflammatory Vascular Disease in Sjogren's Syndrome in Inflammatory Vascular Disease (ed. C. Weyland) (in press)
209. Fox, R. (2000) Sjogren's Syndrome: The interaction of immune, hormonal and neurocrine factors in pathogenesis and treatment. in Molecular Basis of Autoimmune Disease (ed. Theofilopoulos) in press.
210. Fox, R. (2000) Sjogren's Syndrome: New Options for Therapy. Medscape (ed. Silberg). (on line at medscape.com)
211. Fox, R. (2000). Sjogren's Syndrome: An autoimmune disorder which remains inadequately treated. *Exp. Opinion Inv Drugs* 9:2007-2015
212. Fox, R., Stern, M., and Michelson, P. (2000) Update in Sjogren's Syndrome. *Current Opinion in Rheumatology* 12: 391-8
213. Cohen, S. Schiff, M., Weaver, A. and Fox, R. (2000) Two year treatment of active rheumatoid arthritis with leflunomide compared with placebo or methotrexate (in press).
214. Helfgott, S. and Fox, R. (2000) Leflunomide: Use if rheumatoid arthritis and potential benefit in other rheumatic disorders. *Up To Date* (ed. P. Schur, Harvard University), an internet based medical textbook for physicians
215. Kremer, J. Fox, R., and Weinblatt: Five year followup on rheumatoid arthritis patients treated with etanercept (in press)
216. Fox, R. and Fisher, A. (2001). The use of muscarinic agonists in Sjogren's syndrome. *Clin Imm* (in press)
217. Fox, R. (2001). The current role of diagnostic imaging studies in the diagnosis of Sjogren's syndrome: editorial. *Arthritis and Rheumatism* (in press).
218. Fox, R. (2001). Update on the pathogenesis and therapy of Sjogren's syndrome. *Scan. J. of Rheum* (in press)

219. Fox, R. and Stern, M. (2001). The Interaction of Immune and Neural Pathways in the Pathogenesis and Treatment of Sjogren's syndrome. Proc Soc. Exp. Med (in press)
220. Fox, R. and Helfgott, S. (2001). Leflunomide: Current status of role in therapy of rheumatoid arthritis and related autoimmune disorders. Up To Date (ed. P. Schur, Harvard University), an internet based medical textbook for physicians
221. Fox, R. (2001). Sjogren's Syndrome. Mechanisms in Rheumatology Scan J. Rheum (in press)
225. Kremer, J., Weinblatt, M., Fox, R., Fleishman, R., and Burge, D. (2003) Etancerpt and Methotrexate Combination Therapy: Continued Observations (Arth Rheum, in press)
226. Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H., Fox, R., Kassan, S. Pillemer, S., Weisman, M. and the EEC Study Group (2002), Ann Rheum Dis (in press) Classification Criteria for Sjogren's Syndrome: A revision Version of the European Criteria proposed by the American-European Consensus Group
227. Fox, R. and Helfgott, S. (2003). Leflunomide: Use in combination therapy of rheumatoid arthritis and related autoimmune disorders. Up To Date (ed. P. Schur, Harvard University), an internet based medical textbook for physicians
228. Fox, R. (2003) Sjogren's syndrome: Evolving Therapies. Expert Opinion in Invest Drugs 12: 247-254
229. Fox, R. (2003) Use of Muscarinic M1 and M3 agonists in the treatment of Sjogren's syndrome in Lacrimal Gland and Tear Film (ed Sullivan et al). Kluwer Acad Plenum Publishers 1107-1112
230. Fox, R. (2004) Head and Neck Manifestations in patients with progressive systemic sclerosis (in Scleroderma, ed by Furst, D. and Clement, P) (in press)
231. Fox, R. (2005). Current Concepts of Sjogren's Syndrome (State of the Art Review) Lancet (in press)
232. Fox, R. (2005). Therapies for Sjogren's syndrome currently in phase I/phase II development. Expert Opinion in Pharmacology (in press).
233. Fox, R. and Simon, L. WebMD (3/05/05)
"The State of the Art Editorial: Controversy over Coxibs"

234. Fox RI. Sjogren's syndrome. *Lancet* 2005;366:321-31.
235. Fox RI. Methotrexate in Patients With Arthralgias in Scleroderma/CREST Syndrome. *Medscape Rheumatology* 2005;7.
236. Fox RI. Can Lymphocytosis Be Associated With Sjogren's Syndrome? *Medscape Rheumatology* 2005;7.
237. Fox RI. Infusion Reactions With Anti-Tumor Necrosis Factor Blockers. *Medscape Rheumatology* 2005;7.
238. Fox RI. Failing Response to Infliximab. *Medscape Rheumatology* 2005;7.
239. Fox RI. What Is the Best Noninvasive Treatment for Digital Ulcers Due to Raynaud's Phenomenon in Scleroderma? *Medscape Rheumatology* 2005;7.
240. Fox RI. Scleroderma, Intolerable Finger Pain, and Progressive Digital Gangrene. *Medscape Rheumatology* 2005;7.
241. Fox RI. What Is the Incidence of Large Bowel Involvement in Systemic Sclerosis? *Medscape Rheumatology* 2005;7.
242. Fox RI. Sjögren's syndrome. *The Lancet* 2005;366:321-31.
243. Fox RI, Lau CS. Highlights of the International Conference and Exhibition of the Modernization of Traditional Chinese Medicine and Health Products. *Medscape Rheumatology* 2005;6:1-12.
- 244.. Pillemer SR, Smith J, Fox RI, Bowman SJ. Outcome measures for Sjogren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. *J Rheumatol* 2005;32:143-9.
245. Fox RI. Is Heparin or Hormonal Therapy Appropriate for a Young Patient With SLE and Antiphospholipid Syndrome? *Medscape Rheumatology* 2006;8.
246. Fox RI. Side Effect of Long-term Cyclosporine Therapy for Dry Eye in RA and Lupus Patients. *Medscape Rheumatology* 2006;8.
247. Fox RI. Can Methotrexate Be Given Safely to Men With RA and Planning to Have Children? *Medscape Rheumatology* 2006;8.
248. Fox RI, Liu AY. Sjogren's syndrome in dermatology. *Clin Dermatol* 2006;24:393-413.
249. Fox RI, Liu AY. Sjögren's syndrome in dermatology. *Clinics in dermatology* 2006;24:393-413.
- 250.. Fox RI, Liu AY. Sjögren's syndrome in dermatology. *Clinics in dermatology* 2006;24:393-413.
251. Fox RI. Autoimmune Diseases and Sjogren's Syndrome, an Autoimmune Exocrinopathy. *Ann N Y Acad Sci* 2007.
252. Fox R, Therapies E. Current Approaches to Managing Inflammatory Manifestations of Sjögren's Syndrome. *Medscape Rheumatology* 2007;554326.
253. Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nature medicine* 2007;1

Additional recent papers

1-22

1. Fox, R.I., et al., *Treatment of Sjögren's syndrome: current therapy and future directions*. *Rheumatology*, 2021. **60**(5): p. 2066–2074.
2. Fox, R.I. and C.M. Fox, *Sjögren's Syndrome: Past, Present and Future*. Sjogren Syndrome-A Clinical Handbook. Elsevier, 2020.
3. Fox, R.I. and C.M. Fox, *Management of Sjögren disease syndrome*, in *Dubois' Lupus Erythematosus and Related Syndromes*. 2025, Elsevier. p. 838–852.
4. Fox, R.I., C.M. Fox, and S.S. McCoy, *Emerging treatment for Sjögren's disease: A review of recent phase II and III trials*. *Expert opinion on emerging drugs*, 2023. **28**(2): p. 107–120.
5. Fox, R., *X-linked genes exhibit skewed expression in Sjogren's disease (SjD): a further step toward understanding the female predominance of autoimmune disease*. *Journal of Molecular Medicine*, 2022. **100**(9): p. 1267–1269.
6. Deboo, A., et al., *Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease*. *Arthritis Care & Research*, 2025.
7. Quartuccio, L., et al., *Shared pathogenetic features between common variable immunodeficiency and Sjögren's syndrome: clues for a personalized medicine*. *Frontiers in immunology*, 2021. **12**: p. 703780.
8. Ramos-Casals, M., et al., *2023 International Rome consensus for the nomenclature of Sjögren disease*. *Nature Reviews Rheumatology*, 2025. **21**(7): p. 426–437.
9. Baeza, D.C., et al., *The eye as a window to oral and pain symptoms in Sjögren's disease*. *British journal of ophthalmology*, 2025. **109**(9): p. 982–989.
10. Bowman, S.J., et al., *Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial*. *The Lancet*, 2022. **399**(10320): p. 161–171.
11. Sanchez, V., et al., *Rethinking Sjögren beyond inflammation: Considering the role of nerves in driving disease manifestations*. *Eye & contact lens*, 2024. **50**(5): p. 200–207.
12. Marvel, J., et al., *POS0447 REAL-WORLD INSIGHTS INTO THE BURDEN OF SJÖGREN'S DISEASE: A PATIENT-CENTERED ANALYSIS*. *Annals of the Rheumatic Diseases*, 2025. **84**: p. 674–675.
13. Marvel, J., et al., *POS0052 REAL-WORLD INSIGHTS INTO THE TREATMENT SATISFACTION AND UNMET NEEDS OF SJÖGREN'S DISEASE: A PATIENT-CENTERED ANALYSIS*. *Annals of the Rheumatic Diseases*, 2025. **84**: p. 362.
14. Sarka, G., et al. *Evidence-based Guidelines for Sjögren's Disease Peripheral Nervous System Manifestations (S38. 004)*. in *Neurology*. 2024. Lippincott Williams & Wilkins Hagerstown, MD.
15. Shields, C., et al., *Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance*. *Ophthalmology Science*, 2025. **5**(6): p. 100843.
16. Dörner, T., et al., *OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF*

- PRIMARY SJOGREN'S SYNDROME*. *Annals of the Rheumatic Diseases*, 2020. **79**: p. 187–188.
17. Dörner, T., et al., *POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL*. *Annals of the Rheumatic Diseases*, 2021. **80**: p. 593–594.
 18. Stern, M.E., et al., *Immunologic basis for development of keratoconjunctivitis sicca in systemic autoimmune diseases: role of innate immune sensors*. *The Ocular Surface*, 2024. **32**: p. 130–138.
 19. Fox, R., et al. *Evidence-Based Guidelines for Sjogren's Disease Peripheral Nervous System Manifestations*. in *ARTHRITIS & RHEUMATOLOGY*. 2024. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
 20. Fox, R., et al. *MULTI-SPECIALTY COLLABORATION IN DEVELOPMENT OF GUIDELINES FOR MANAGEMENT OF NEUROLOGICAL MANIFESTATIONS OF SJOGREN'S DISEASE*. in *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*. 2022. CLINICAL & EXPER RHEUMATOLOGY VIA SANTA MARIA 31, 56126 PISA, ITALY.
 21. Mariette, X., et al., *Ianalumab (VAY736), inhibition des récepteurs BAFF et déplétion des lymphocytes B pour le traitement du syndrome de Sjögren primitif: résultats d'une étude internationale, randomisée, contrôlée par placebo de détermination de doses chez 190 patients*. *Revue du Rhumatisme*, 2020. **87**: p. A7.
 22. Shaikh, F.S., et al., *Challenges and promise of targeting miRNA in rheumatic diseases: A computational approach to identify miRNA association with cell types, cytokines, and disease mechanisms*. *Frontiers in immunology*, 2024. **14**: p. 1322806.

Recent Book Chapters for Expert Opinion

1. Fox RI, Fox CM, Gottenberg JE, Dörner T. Treatment of Sjögren's syndrome: current therapy and future directions. *Rheumatology* 2021;60(5):2066–2074.
2. Fox RI, Fox CM. Sjögren's Syndrome: Past, Present and Future. *Sjogren Syndrome-A Clinical Handbook* Elsevier 2020.
3. Fox RI, Fox CM. Management of Sjögren disease syndrome. *Dubois' Lupus Erythematosus and Related Syndromes*: Elsevier; 2025:838–852.
4. Fox RI, Fox CM, McCoy SS. Emerging treatment for Sjögren's disease: A review of recent phase II and III trials. *Expert opinion on emerging drugs* 2023;28(2):107–120.
5. Fox R. X-linked genes exhibit skewed expression in Sjogren's disease (SjD): a further step toward understanding the female predominance of autoimmune disease. *Journal of Molecular Medicine* 2022;100(9):1267–1269.
6. Deboo A, Fox R, Hammitt KM, et al. Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease. *Arthritis Care & Research* 2025.

7. Quartuccio L, De Marchi G, Longhino S, et al. Shared pathogenetic features between common variable immunodeficiency and Sjögren's syndrome: clues for a personalized medicine. *Frontiers in immunology* 2021;12:703780.
8. Ramos-Casals M, Baer AN, Brito-Zerón MDP, et al. 2023 International Rome consensus for the nomenclature of Sjögren disease. *Nature Reviews Rheumatology* 2025;21(7):426–437.
9. Baeza DC, Sanchez V, Goldhardt R, et al. The eye as a window to oral and pain symptoms in Sjögren's disease. *British journal of ophthalmology* 2025;109(9):982–989.
10. Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. *The Lancet* 2022;399(10320):161–171.
11. Sanchez V, Dobzinski N, Fox R, Galor A. Rethinking Sjögren beyond inflammation: Considering the role of nerves in driving disease manifestations. *Eye & contact lens* 2024;50(5):200–207.
12. Marvel J, Kenney G, Church J, et al. POS0447 REAL-WORLD INSIGHTS INTO THE BURDEN OF SJÖGREN'S DISEASE: A PATIENT-CENTERED ANALYSIS. *Annals of the Rheumatic Diseases* 2025;84:674–675.
13. Marvel J, Kenney G, Church J, et al. POS0052 REAL-WORLD INSIGHTS INTO THE TREATMENT SATISFACTION AND UNMET NEEDS OF SJÖGREN'S DISEASE: A PATIENT-CENTERED ANALYSIS. *Annals of the Rheumatic Diseases* 2025;84:362.
14. Sarka G, Deboo A, Fox R, et al. Evidence-based Guidelines for Sjögren's Disease Peripheral Nervous System Manifestations (S38. 004). *Neurology: Lippincott Williams & Wilkins Hagerstown, MD*; 2024:5288.
15. Shields C, Donthineni PR, Muralidhar R, et al. Serological Influences on Dry Eye: Insights from the Sjögren's International Collaborative Clinical Alliance. *Ophthalmology Science* 2025;5(6):100843.
16. Dörner T, Bowman S, Fox R, et al. OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME. *Annals of the Rheumatic Diseases* 2020;79:187–188.
17. Dörner T, Bowman S, Fox R, et al. POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. *Annals of the Rheumatic Diseases* 2021;80:593–594.
18. Stern ME, Theofilopoulos AN, Steven P, et al. Immunologic basis for development of keratoconjunctivitis sicca in systemic autoimmune diseases: role of innate immune sensors. *The Ocular Surface* 2024;32:130–138.
19. Fox R, Deboo A, Baker M, et al. Evidence-Based Guidelines for Sjogren's Disease Peripheral Nervous System Manifestations. *ARTHRITIS & RHEUMATOLOGY: WILEY* 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2024:2874–2875.

20. Fox R, Deboo A, Hammitt K, et al. MULTI-SPECIALTY COLLABORATION IN DEVELOPMENT OF GUIDELINES FOR MANAGEMENT OF NEUROLOGICAL MANIFESTATIONS OF SJOGREN'S DISEASE. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY: CLINICAL & EXPER RHEUMATOLOGY VIA SANTA MARIA 31, 56126 PISA, ITALY; 2022:77–78.
21. Mariette X, Bowman S, Fox R, et al. Ianalumab (VAY736), inhibition des récepteurs BAFF et déplétion des lymphocytes B pour le traitement du syndrome de Sjögren primitif: résultats d'une étude internationale, randomisée, contrôlée par placebo de détermination de doses chez 190 patients. *Revue du Rhumatisme* 2020;87:A7.
22. Shaikh FS, Siegel RJ, Srivastava A, Fox DA, Ahmed S. Challenges and promise of targeting miRNA in rheumatic diseases: A computational approach to identify miRNA association with cell types, cytokines, and disease mechanisms. *Frontiers in immunology* 2024;14:1322806.

Other refs since 2024 can be found on PubMed